Kamran Sophia C, Efstathiou Jason A
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Front Oncol. 2021 May 7;11:675311. doi: 10.3389/fonc.2021.675311. eCollection 2021.
Radiation therapy plays a crucial role for the management of genitourinary malignancies, with technological advancements that have led to improvements in outcomes and decrease in treatment toxicities. However, better risk-stratification and identification of patients for appropriate treatments is necessary. Recent advancements in imaging and novel genomic techniques can provide additional individualized tumor and patient information to further inform and guide treatment decisions for genitourinary cancer patients. In addition, the development and use of targeted molecular therapies based on tumor biology can result in individualized treatment recommendations. In this review, we discuss the advances in precision oncology techniques along with current applications for personalized genitourinary cancer management. We also highlight the opportunities and challenges when applying precision medicine principles to the field of radiation oncology. The identification, development and validation of biomarkers has the potential to personalize radiation therapy for genitourinary malignancies so that we may improve treatment outcomes, decrease radiation-specific toxicities, and lead to better long-term quality of life for GU cancer survivors.
放射治疗在泌尿生殖系统恶性肿瘤的治疗中起着关键作用,技术进步已使治疗效果得到改善,治疗毒性降低。然而,有必要进行更好的风险分层并识别适合接受相应治疗的患者。影像学和新型基因组技术的最新进展可以提供更多个性化的肿瘤和患者信息,从而进一步为泌尿生殖系统癌症患者的治疗决策提供参考和指导。此外,基于肿瘤生物学的靶向分子疗法的开发和应用可以产生个性化的治疗建议。在本综述中,我们讨论了精准肿瘤学技术的进展以及当前在个性化泌尿生殖系统癌症管理中的应用。我们还强调了将精准医学原则应用于放射肿瘤学领域时的机遇和挑战。生物标志物的识别、开发和验证有可能使泌尿生殖系统恶性肿瘤的放射治疗个性化,从而改善治疗效果,降低放射特异性毒性,并为泌尿生殖系统癌症幸存者带来更好的长期生活质量。